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CONSENSUS
The diagnosis and treatment of peripheral 
lymphedema: 2016 Consensus Document  
of the International Society of Lymphology
This International Society of Lymphology (ISL) Consensus Document is the latest revision of the 1995 Document 
for the evaluation and management of peripheral lymphedema [1]. It is based upon modifications: [A] suggested 
and published following the 1997 XVI International Congress of Lymphology (ICL) in Madrid, Spain [2], discussed 
at the 1999 XVII ICL in Chennai, India [3], and considered/confirmed at the 2000 (ISL) Executive Committee 
meeting in Hinterzarten, Germany [4]; [B] derived from integration of discussions and written comments ob-
tained during and following the 2001 XVIII ICL in Genoa, Italy as modified at the 2003 ISL Executive Committee 
meeting in Cordoba, Argentina [5]; [C] suggested from comments, criticisms, and rebuttals as published in the 
December 2004 issue of Lymphology [6]; [D] discussed in both the 2005 XX ICL in Salvador, Brazil and the 
2007 XXI ICL in Shanghai, China and modified at the 2008 Executive Committee meeting in Naples, Italy [7, 8]; 
[E] modified from discussions and written comments from the 2009 XXII ICL in Sydney, Australia, the 2011 
XXIII ICL in Malmö, Sweden, the 2012 Executive Committee Meetings [9],and [F] from discussions at the 2013 
XXIV ICL in Rome, Italy, and the 2015 XXV ICL in San Francisco, USA, as well as multiple written comments 
and feedback from Executive Committee and other ISL members during the 2016 drafting.
The document attempts to amalgamate the broad spectrum of protocols and practices advocated worldwide 
for the diagnosis and treatment of peripheral lymphedema into a coordinated proclamation representing 
a “Consensus” of the international community based on various levels of evidence. The document is not meant 
to override individual clinical considerations for complex patients nor to stifle progress. It is also not meant 
to be a legal formulation from which variations define medical malpractice. The Society understands that 
in some clinics the method of treatment derives from national standards while in others access to medical 
equipment and supplies is limited; therefore the suggested treatments might be impractical. Adaptability and 
inclusiveness does come at the price that members can rightly be critical of what they see as vagueness or 
imprecision in definitions, qualifiers in the choice of words (e.g., the use of “may... perhaps... unclear”, etc.) and 
mentions (albeit without endorsement) of treatment options supported by limited hard data. Most members 
are frustrated by the reality that NO treatment method has really undergone a satisfactory meta-analysis (let 
alone rigorous, randomized, stratified, long-term, controlled study). With this understanding, the absence of 
definitive answers and optimally conducted clinical trials, and with emerging technologies and new approaches 
and discoveries on the horizon, some degree of uncertainty, ambiguity, and flexibility along with dissatisfaction 
with current lymphedema evaluation and management is appropriate and to be expected.
We continue to struggle to keep the document concise while balancing the need for depth and details. With 
these considerations in mind, we believe that this 2016 version presents a Consensus that embraces the 
entire ISL membership, rises above national standards, identifies and stimulates promising areas for future 
research, and represents the best judgment of the ISL membership on how to approach patients with periph-
eral lymphedema in the light of currently available evidence. Therefore, the document has been, and should 
Reprinted from: Lymphology 49 (2016) 170–184, by permission of International Society of Lymphology
172
Acta Angiol, 2017, Vol. 23, No. 4
www.journals.viamedica.pl/acta_angiologica
General considerations
As a fundamental starting point, lymphedema is an ex-
ternal (and/or internal) manifestation of lymphatic system 
insufficiency and deranged lymph transport Some members 
prefer to define peripheral lymphedema as a symptom or 
sign resulting from underlying lymphatic disease. It is defined 
as an illness by the International Classification of Diseases 
from the World Health Organization. Lymphedema may 
be an isolated phenomenon or associated with a multitude 
of other disabling local sequelae or even life-threatening 
systemic syndromes. Its nature may be acute, transitory, 
or chronic. In its purest form, the central disturbance 
is a low output failure (mechanical insufficiency) of the 
lymphvascular system; that is, overall lymphatic transport 
is reduced. This derangement arises either from congenital 
lymphatic dysplasia (primary lymphedema) or anatomical 
obliteration, such as after radical operative dissection 
(e.g., axillary or retroperitoneal nodal sampling), irradiation, 
or from repeated lymphangitis with lymphangiosclerosis 
(secondary lymphedema) or as a consequence of functional 
deficiency (e.g., lymphangiospasm, stasis, and valvular insuf-
ficiency in primary or secondary lymphedema. Nonetheless, 
the common denominator is that the lymphatic system 
(whether vessels, nodes, interstitium, etc, or combina-
tions) transport has fallen below the capacity needed to 
handle the presented load of microvascular filtrate includ-
ing plasma protein and cells that normally leak from the 
bloodstream into the interstitium. Swelling is produced by 
accumulation in the extracellular space of excess water, 
filtered/ diffused plasma proteins, extravascular blood 
cells and parenchymal/stromal cell products. This process 
culminates in proliferation of parenchymal and stromal 
elements with excessive deposition of extracellular matrix 
substances and adipose tissue. High output failure (dynamic 
insufficiency) of the lymph circulation, on the other hand, 
occurs when a normal or increased transport capacity of 
intact lymphatics is overwhelmed by an excessive burden 
of blood capillary filtrate. Examples include hepatic cirrho-
sis (ascites), hypoalbuminemia associated with nephrotic 
syndrome (anasarca), right heart failure, and deep venous 
insufficiency of the leg (peripheral edema). Although the 
final pathway is the manifestation of tissue edema whenev-
er lymph formation exceeds lymph absorption, the latter 
entities should properly be distinguished from lymphedema, 
which is characterized by decreased lymphatic transport. 
In some syndromes where high output lymphatic transport 
failure is longstanding, a gradual functional deterioration of 
the draining lymphatics may supervene and thereby reduce 
overall transport capacity.
A reduced lymphatic circulatory capacity then develops 
in the face of increased blood capillary filtration. Examples 
include recurring infection, thermal burns, and repeated al-
lergic reactions. These latter conditions are associated with 
“safety valve insufficiency” of the lymphatic system where 
the lymph load increases over “normal” flow to eventually 
become overwhelmed and this can be considered a mixed 
form of edema/lymphedema and as such are particularly 
troublesome to treat.
Peripheral lymphedema associated with chylous and 
non-chylous reflux syndromes is an infrequent but com-
plex condition that requires specific diagnostic measures 
and treatment methods. There are other complicating 
diagnoses (e.g., genetic with Turner or Noonan syndromes 
or arterial/ venous malformations) which require additional 
considerations.
In the treatment of “classical” lymphedema of the limbs 
(that is, peripheral lymphedema), improvement in swelling 
can usually be achieved by non-operative therapy. Because 
lymphedema most often becomes a chronic, generally in-
curable condition, it generally requires, as do other chronic 
disorders, lifelong care and attention along with psycho-
social support. The continued need for therapy does not 
mean a priori that treatment is unsatisfactory, although 
often it is less than optimal. For example, patients with 
diabetes mellitus continue to need drugs (insulin) or special 
continue to be, challenged and debated in the pages of Lymphology (e.g., as Letters to the Editor) and ideally 
will remain a continued focal point for robust discussion at local, national and international conferences in 
lymphology and related disciplines. We further anticipate as experience evolves and new ideas and technologies 
emerge that this “living document” will undergo further periodic revision and refinement as the practice and 
conceptual foundations of medicine and specifically lymphology change and advance.
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diet (low calorie, low sugar) in order to maintain metabolic 
homeostasis. Similarly, patients with chronic venous insuf-
ficiency require lifelong external compression therapy to 
minimize edema, lipodermatosclerosis and skin ulceration 
(treatments may be preventative if initiated early). Com-
pliance and adherence of the patient is also essential to 
an improved outcome. With chronic venous insufficiency, 
poor patient compliance may be causally associated with 
progressive skin ulceration, hyperpigmentation, and other 
trophic changes in the lower leg. Similarly, failure to control 
lymphedema may lead to repeated infections (cellulitis/ 
/lymphangitis), progressive elephantine trophic changes in the 
skin, sometimes crippling invalidism and on rare occasions, 
the development of a highly lethal lymphangiosarcoma 
(widely known as Stewart-Treves syndrome).
The particular setting of examination, diagnosis, and 
treatment (clinic, hospital, properly designed teams, etc.) 
as well as patient condition (ambulation, portability, fra-
gility, etc.) can all impact individualized patient care and 
treatment.
Prevention/Early Identification and Treatment
The recent promulgation of lists of risk factors for sec-
ondary lymphedema has become a highlighted issue due to 
publications of “do’s and don’ts”. These are largely anecdo-
tal and not sufficiently investigated. While some precautions 
rest on solid physiological principles (e.g., avoiding excessive 
heat on an “at risk” limb, not having chemotherapy admin-
istered into the limb unless medically necessary, or trying to 
avoid infections), others are less supported. Consistently, 
a BMI >25, axillary node dissection, radiation to the axilla, 
and appearance of cellulitis following operation are more 
firmly supported as true risks. It must be noted that most 
published studies on incidence of secondary lymphedema of 
the extremities report less than 50% chance of developing 
lymphedema with nodal basin operations, irradiation, and 
taxane-based chemotherapy (substantially less with more 
conservative treatments, e.g., lumpectomy with sentinel 
lymph node biopsy). Therefore, standard use of some of 
these “don’ts” for risk reduction of lymphedema may not 
be appropriate and possibly subjects patients to therapies 
which are unsupported until a point in the future when 
evaluation and prognostication evidence has demonstrated 
more clearly specific risks and the corresponding preventa-
tive measures.
The concepts of “primary” and “secondary” prevention 
(including risk reduction) are receiving increased attention. 
Operative imaging techniques to lessen lymphatic system im-
pact by identifying lymphatic vessels to avoid during proce-
dures as well as performing prophylactic lymphaticvenous 
shunts in high-risk patients are being explored. Exercise, 
self-MLD, and education for prevention of secondary 
lymphedema are also undergoing investigation. Radiation 
treatment techniques are continually evolving to reduce and 
isolate secondary damage. Further research is needed, and 
all such techniques will have to be tempered by the actual 
risk of developing lymphedema in specific populations based 
on emerging incidence evidence.
Recently, the question of when to monitor a patient has 
emerged for patients undergoing cancer treatment. Pro-
spective surveillance models (PSM) have been developed to 
address early detection of lymphedema leading to earlier 
and more efficacious treatment. The prospective sur-
veillance model involves a preoperative cancer treatment 
assessment where baseline limb volume and functional 
mobility measurements are established (some clinics with 
the availability of bioimpedance spectroscopy may utilize 
that to detect early changes in tissue fluid accumulation).
Patients are then followed in a prospective manner 
(e.g., 3 month intervals for the first year during and post-
cancer treatment and then less frequently). Followup 
visits include psychosocial support and reassessment of 
limb volume and functional mobility to offer a comparison 
to baseline measures to enable identification of meaningful 
change associated with sub-clinical onset of lymphedema. 
Sub-clinical lymphedema is measurable at low diagnostic 
thresholds (3–5% volume change from baseline in swelling 
not due to weight change — i.e. determined by measuring 
both limbs) and may initially present in only one segment 
of the limb. Identifying subclinical lymphedema facilitates 
early, conservative intervention and may reduce the likeli-
hood that the condition will progress to a chronic advanced 
stage. Identifying and treating lymphedema at an early stage 
offers greater treatment success and potential cost sav-
ings with conservative management programs including 
compression garments, education for self-care, self-MLD 
(and/or partner/care giver-MLD), psychosocial support and 
exercise. Early identification may also offer the opportunity 
for lymphaticvenous shunts in appropriate situations to offer 
a potential life-long avoidance of further treatment.
Staging of lymphedema
Most ISL members rely on a three stage scale for 
classification of a lymphedematous limb with an increasing 
number recognizing Stage 0 (or Ia) which refers to a latent 
or subclinical condition where swelling is not yet evident 
despite impaired lymph transport, subtle alterations in tissue 
fluid/composition, and changes in subjective symptoms. It 
may exist months or years before overt edema occurs 
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(Stages I–III). Assessment of early fluid changes can be 
accomplished using bioimpedance spectroscopy or tissue 
dielectric constant analysis. Stage I represents an early ac-
cumulation of fluid relatively high in protein content (e.g., in 
comparison with “venous” edema) which subsides with limb 
elevation. Pitting may occur. An increase in various types 
of proliferating cells may also be seen. Stage II signifies that 
limb elevation alone rarely reduces the tissue swelling and 
pitting is manifest. Later in Stage II, the limb may not pit 
as excess subcutaneous fat and fibrosis develop. Stage III 
encompasses lymphostatic elephantiasis where pitting can 
be absent and trophic skin changes such as acanthosis, al-
terations in skin character and thickness, further deposition 
of fat and fibrosis, and warty overgrowths have developed. 
It should be noted that a limb may exhibit more than one 
stage, which may reflect alterations in different lymphatic 
territories.
These Stages only refer to the physical condition of 
the extremities. A more detailed and inclusive classifica-
tion needs to be formulated in accordance with im-
proved understanding of the pathogenic mechanisms of 
lymphedema (e.g., nature and degree of lymphangiodys-
plasia, lymph flow perturbations, and nodal dysfunction 
as defined by anatomic features and physiologic imaging 
and testing) and underlying genetic disturbances, which 
are gradually being elucidated. Recent publications com-
bining both physical (phenotypic) findings with functional 
lymphatic imaging as well as those classifications which 
propose inclusion of disability grading, assessment of 
inflammation, and even immunohistochemical changes 
determined by biopsy of nodes/vessels may be forecasting 
the future evolution of staging. In addition, incorpo-
ration of genotypic information, expanded from what 
is available even in current screening, would further 
advance staging and classification of patients with pe-
ripheral (and other) lymphedema.
Within each Stage, a limited but nonetheless functional 
severity assessment has utilized simple volume differences 
assessed as minimal (>5-<20% increase in limb volume), 
moderate (20–40% increase), or severe (>40% increase). 
Some clinics prefer to use > 5–10% as minimal and >10-
<20% as mild. Volume differentials are most commonly 
determined using circumferential measurement due to 
wide availability and low cost. A flexible nonstretch tape 
is preferred and the truncated cone formula is utilized for 
calculating volume. Water displacement volumetry is used 
in some clinics for arm or lower leg volumes although there 
are some practical limits (e.g., size of limb, measuring areas 
near the root of the limb, and hygiene issues). Perometry 
provides high accuracy by using infrared light beams to 
estimate limb volume but the equipment cost is significant 
for smaller clinics and the hand and foot are not included.
Clinicians also incorporate factors such as extensive-
ness, occurrence of erysipelas attacks, inflammation, and 
other descriptors or complications into their own individual 
severity determinations.
Some healthcare professionals focus on disability rating 
utilizing the World Health Organization’s guidelines for the 
International Classification of Functioning, Disability, and 
Health (ICF). Quality of Life issues (psychosocial, social, 
emotional, physical disabilities, etc.) may also be addressed 
by individual clinicians and groups, and note that these 
can positively or negatively impact therapy and compliance 
(maintenance).
Diagnosis
An accurate diagnosis of lymphedema is essential for 
appropriate therapy. In most patients, the diagnosis of 
lymphedema can be readily determined from the clinical 
history and physical examination. In other patients, con-
founding conditions such as morbid obesity, lipohyperdys-
trophy, endocrine dysfunction, venous insufficiency, unrec-
ognized trauma, and repeated infection may complicate 
the clinical picture. Moreover, in considering the basis of 
unilateral extremity lymphedema, especially in adults, solid 
organ tumors (primary and/or metastatic), lymphomas, and 
soft tissue sarcomas which may obstruct or invade more 
proximal lymphatics need to be considered. For these 
reasons, a thorough medical evaluation is indispensable 
before embarking on lymphedema treatment. Co-morbid 
conditions such as congestive heart failure, hypertension, 
thyroid abnormalities, cerebrovascular disease including 
stroke, and vascular malformations may also influence the 
diagnosis and therapeutic approach undertaken.
Imaging
If the diagnosis of lymphedema is unclear or in need of 
better definition for prognostic or therapeutic considera-
tions, consultation with a clinical lymphologist or referral 
to a lymphologic center if accessible is recommended. 
Commonly, ultrasound techniques are first used to assess 
and rule out venous disease in many centers (although this 
is also used in some centers to assess lymphedema). The 
diagnostic tool of isotope lymphography (also termed lym-
phoscintigraphy — for both vessels and nodes — or more 
commonly lymphangioscintigraphy despite its reference only 
to the vessels) has proved extremely useful for depicting the 
specific lymphatic abnormality. Where specialists in nuclear 
medicine are available, lymphangioscintigraphy (LAS) has 
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largely replaced conventional oil contrast lymphography 
for visualizing the lymphatic network. Although LAS has not 
been strictly standardized (various radiotracers and radi-
oactivity doses, different injection volumes, intracutaneous 
versus subcutaneous or subfascial injections, one or more 
injections, different protocols of passive and active physical 
activity, varying imaging times, static and/or dynamic tech-
niques), the images, which can be easily repeated, offer 
remarkable insight into lymphatic structural abnormalities 
and (dys)function. The etiology is not necessarily determined 
from the image alone. LAS has been used frequently in 
newborns and children obtaining reproducible, pre-clinical 
diagnostic images.
LAS provides dynamic images of both lymphatics and 
lymph nodes in the peripheral and central system as well as 
semi-quantitative data on radiotracer (lymph) transport, 
and it does not require dermal injections of blue-dye (as 
often used for example in axillary or groin sentinel node 
visualize(correctly termed lymphadenoscintigraphy). Blue 
dye injection is occasionally complicated by an allergic skin 
reaction or serious anaphylaxis. Moreover, clinical interpre-
tation of lymphatic function after vital dye injection alone 
(“the blue test”) can be misleading. Direct oil contrast 
lymphography, which is cumbersome and occasionally 
associated with minor and even major complications, is 
usually reserved for complex conditions such as chylous 
reflux syndrome and thoracic duct injury, where LAS can 
provide at least preliminary diagnostic images for screening. 
Non-invasive duplex-Doppler studies and occasionally phle-
bography are useful for examining the deep venous system 
and supplement or complement the evaluation of extremity 
edema. Other diagnostic and investigational tools used to 
elucidate lymphangiodysplasia/lymphedema syndromes (in-
cluding newborns and children) include magnetic resonance 
imaging (MRI) — including MR lymphography (MRL) and 
MR angiography techniques, computed tomography (CT), 
CT lymphograms, 3-D oil contrast lymphography, CT-
SPECT, ultrasonography (US), indirect (water soluble) 
lymphography (IL), near infrared fluorescent imaging 
(NIRF) (also known as ICG lymphography) and fluorescent 
microlymphangiography (FM). NIRF has been increasingly 
used in some centers for examining the superficial lymphatic 
system and in the operative setting. Both peripheral MRL 
and NIRF are becoming more widespread in use around 
the world despite limitations for imaging the deeper lym-
phatic system. DEXA (dual-energy X-ray absorptiometry 
or biphotonic absorptiometry) may help classify and define 
a lymphedematous limb but its greatest potential use may 
be to assess the chemical composition of limb swelling (es-
pecially increased fat deposition, which by its added weight 
can lead to muscle hypertrophy). IL and FM are best suited 
to depict initial lymphatics and more superficial collectors 
and accordingly have limited clinical usefulness albeit valuable 
in research investigations. US has found practical value in 
depicting the “dance” of the living adult worms in scrotal 
lymphatic filariasis, and it is also increasingly used to highlight 
tissue alterations.
Genetics
Genetic testing has become practical and commercially 
available to screen for a number of specific hereditary syn-
dromes with discrete gene mutations such as lymphedema-
distichiasis (FOXC2), some forms of Milroy disease (FLT-4), 
and hypotrichosislymphedema-telangiectasia (SOX18), as 
well as a variety of chromosomal abnormalities.
Other genes identified include: Generalized Lymphatic 
Dysplasia (Hennekam syndrome) (CCBE1, FAT4), Inher-
ited Lymphedema Types 1C (GJC2) and 1D (VEGFC), 
Lymphedema-Choanal Atresia (PTPN14), Emberger 
(GATA2), oculodento-digital syndrome (GJA1), lymphede-
ma-lymphangiectasia (HGF), and hereditary lymphedema 
III (PIEZO1). The future holds promise that such testing 
for other known mutations and chromosomal defects, as 
well as newly discovered ones, combined with careful phe-
notypic descriptions, will become routine to classify familial 
lymphangiodysplastic (correctly lymphdysplastic since nodes 
can also be involved) syndromes and other congenital/genet-
icdysmorphogenic disorders characterized by lymphedema, 
lymphangiectasia, and lymphangiomatosis. Algorithms have 
been developed to assist clinicians in phenotyping and di-
recting genetic analysis.
There are many other clinical syndromes with lymphe- 
dema as a component. Some of these have genes identified 
[Noonan (PTPN11, KRAS, SOS1, and others); micro-
cephaly-chorioretinopathy-lymphedema-mental retardation 
(MCLMR) (KIF11); Proteus syndrome (AKT1); Clove 
(fibroadipose hyperplasia (PIK3CA); Park-Weber syn-
drome (capillary malformation-arteriovenous malformation) 
(RASA1); and lymphatic related hydrops fetalis (LRHG) 
(EPHB4)] while others still have no known associated 
genes. It is important to consider that the number of de 
novo germinal variations in these genes is increasing. In ad-
dition, recent and ongoing research is exploring a possible 
genetic (and epigenetic) basis underlying increased risk of 
developing secondary lymphedema after treatment involv-
ing injury to the lymphatic system.
Newer genetic techniques such as genome-wide as-
sociation studies (GWA study, or GWAS), whole genome 
sequencing (WGS), and whole exome sequencing (WES) 
are rapidly advancing genetic analysis. A targeted Next 
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Generation Sequencing panel examining all known genes 
associated with lymphedema is currently the most common 
choice for analyzing hereditary forms of lymphedema. As 
costs decrease, more patients will undergo such analysis and 
more single, multiple, and interacting variants will be identi-
fied to help classify individuals with genetic defects related to 
the lymphatic system. These more refined classifications may 
impact diagnosis (perhaps allowing proactive rather than 
reactive care), future treatments (targeted therapy), and 
quality of life as precision medicine is applied to lymphatic 
diseases. These newer techniques will also contribute to 
prenatal diagnosis and, combined with multimodal imaging, 
to the early diagnosis and potential treatment of congenital 
lymphatic conditions.
Biopsy/Lymph Node Exam
Caution should be exercised before removing enlarged 
regional lymph nodes in the setting of longstanding periph-
eral lymphedema as the histologic information is seldom 
helpful, and such excision may aggravate distal swelling. 
Fine needle aspiration with cytological examination by 
a skilled pathologist is a useful alternative if malignancy is 
suspected. Use of sentinel node biopsy in the axilla or 
groin for staging malignancy such as breast and melanoma 
appears to have substantially lessened the incidence of 
peripheral lymphedema by discouraging removal of normal 
lymph nodes; however, an increased number of sentinel 
nodes taken may reduce this protective effect.
Treatment
Therapy of peripheral lymphedema is divided into con-
servative (non-operative) and operative methods. Applicable 
to both methods is an understanding that meticulous skin 
hygiene and care (cleansing, low pH lotions, emollients) 
is of the utmost importance to the success of virtually all 
treatment approaches, as is patient education and training. 
Basic motion exercises of the extremities (muscle pumping 
exercises), especially combined with external limb com-
pression and preferably performed as daily life activities 
(walking, yoga, bicycling, and climbing stairs) are useful. 
Limb elevation (specifically bed rest if indicated) is also 
helpful to the appropriate patient undergoing treatment. 
Newer studies have indicated that more vigorous exercise 
can be undertaken under the proper conditions, and strong 
evidence is now available on the safety of resistance exercise 
in controlled trials for breast cancer-related lymphedema. 
Evidence has not been published on how soon after the 
operation exercises (and what type) should be initiated, 
and this area needs further study. As previously stated, 
even widely used treatment methods have yet to undergo 
sufficient meta-analysis of multiple studies which have been 
rigorous, well-controlled, and with sufficient followup. Sat-
isfactory studies comparing different methods of treatment 
do not exist, and advocates of all methods report that 
earlier treatment is optimal for the best results. It is also 
worth considering that a combination of therapies may be 
best for some patients, but these combinations are even 
less frequently studied in comparison trials. Use of various 
treatment options is appropriate for neonates and chil-
dren with careful consideration from the treatment team. 
Treatments can take place in the outpatient setting, a day 
hospital, or during hospitalization as judged appropriate by 
the medical team for each patient.
Non-operative Treatment
Physical therapy and adjuvants
a. Complex Decongestive Therapy (CDT) also known 
as Combined Physical Therapy (CPT) or Complex 
Decongestive Physiotherapy (CDP) (among others) 
is backed by longstanding experience and generally 
involves a two-stage treatment program that can be 
applied to both children and adults for most areas of the 
body. The first phase consists of skin care, a specific light 
manual massage (manual lymphatic drainage-MLD) and 
sometimes deeper techniques with patients classified 
above Stage I, using muscle pumping exercises, and 
compression typically applied with multilayered bandage 
wrapping. Phase 2 (initiated promptly after Phase 1) 
aims to conserve and optimize the results obtained in 
Phase 1. It consists of compression by a low-stretch 
elastic stocking or sleeve, skin care, continued “reme-
dial” exercise, and repeated MLD as needed.
 Prerequisites of successful combined physio-
therapy are the availability of physicians (i.e., clinical 
lymphologists), nurses, physiotherapists, occupational 
and other therapists specifically trained, educated, and 
experienced in this method. In addition, factors such 
as the acceptance of health insurers to underwrite the 
cost of treatment, willingness of biomaterials industry to 
produce and provide high quality affordable products, 
and an understanding of the holistic needs of each 
patient impact success. Compressive bandages, when 
applied incorrectly, can be harmful and/or useless.
 Accordingly, such multilayer wrapping should be 
carried out only by professionally trained personnel. 
Multiple manufactured devices/garments to assist in 
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compression (i.e., pull on, velcro-assisted, quilted, etc.) 
may relieve some patients of the bandaging burden and 
perhaps facilitate compliance with the full treatment 
program, and some clinics find that patient self-care and 
risk reduction strategies help maintain edema reduction 
(although neither of these has undergone rigorous study).
 CDT may also be of use for palliation as, for exam - 
ple, to control secondary lymphedema from tu-
mor-blocked lymphatics. Treatment is typically per-
formed in conjunction with chemoor radiotherapy 
directed specifically at producing tumor regression. 
Only theoretically, massage and mechanical compression 
could mobilize dormant tumor cells; however lymph 
flow does not stop after a cancer diagnosis and only 
diffuse carcinomatous infiltrates which have already 
spread to lymph collectors as tumor thrombi might be 
mobilized by such treatment. Because the longterm 
prognosis for such an advanced patient is usually dismal, 
any reduction in morbid swelling is decidedly palliative.
 A prescription for elastic garments (custom 
made with correctly-obtained specific measurement if 
needed) to maintain lymphedema reduction after CDT 
is essential for long-term care. Preferably, a physician 
(sometimes with assistance of highly-skilled specialists) 
should prescribe the compression garment to avoid 
inappropriate usage in a patient with medical contrain-
dications such as arterial disease, painful postphlebitic 
syndrome or occult visceral neoplasia. Generally the 
highest compression level tolerated (~20–60 mmHg) 
by the patient is likely to be the most beneficial. Some 
clinics prefer to use only flat-knit garments while others 
use both flat and round-knit garments (or combination). 
Sometimes patient selection, choice, physical ability as 
well as cost need to be taken into consideration particu-
larly when assessing mobility and future compliance.
 Failure of CDT is confirmed only when intensive 
nonoperative treatment in a clinic specializing in man-
agement of peripheral lymphedema and directed by an 
experienced clinical lymphologist has been unsuccessful.
b. Compression garments alone have been successfully 
used for treatment particularly in breast cancer-relat-
ed lymphedema at first indication of fluid build-up and 
minimal volume change as well as in early Stage I. Data 
on the use for later stages are very limited.
c. Massage alone. Performed as an isolated technique, 
classical massage or effleurage generally does not 
appear to be of benefit. Moreover, if performed overly 
vigorously, massage (classical or others, not MLD) 
may damage lymphatic vessels or their attachment to 
surrounding tissues.
 There are several published studies demonstra- 
ting the utility of MLD monotherapy in specific popu-
lations (i.e., early breast cancer-related lymphedema 
and newly established and/or mild lymphedema without 
adipose or fibrosis tissue deposition) but there is a need 
for more robust studies to generate convincing evidence. 
This is counterbalanced against several systematic re-
views with metaanalysis concluding that MLD (in breast 
cancer-related arm lymphedema) has no or very little 
additional effect on compression therapy.
 There are some published reports supporting 
the use of manual lymph drainage as a monotherapy for 
lymphedema prevention after cancer surgery.
d. Intermittent pneumatic compression. Pneumomassage 
is usually a two-phase program. After external com-
pression therapy is applied, preferably by a sequential 
gradient “pump,” form-fitting low-stretch elastic stock-
ings or sleeves are used to maintain edema reduction. 
Newer devices that simulate manual massage and design 
improvements for area of coverage, ease of use, and se-
quence/actions may increase patient compliance par-
ticularly for those who cannot complete both phases of 
CDT (e.g., exercise with compression). Displacement 
of edema more proximally in the limb and genitalia and 
the development of a fibrosclerotic ring at the root of 
the extremity with exacerbated obstruction of lymph 
flow need to be assiduously avoided by careful observa-
tion. Combining pneumatic compression with manual 
lymph drainage has been suggested but not sufficiently 
evaluated.
e. Thermal therapy. Although combinations of heat, skin 
care, and external compression have been advocated 
for and successfully used by practitioners in Europe and 
Asia for thousands of patients, the role and value of 
thermotherapy alone without compression in the man-
agement of lymphedema remains unclear and further 
rigorous studies are needed. Studies have shown that 
under bandaging the skin temperature slowly rises, and 
it is proposed that this lower level thermal therapy is 
helpful. Some centers use far infrared light as an adjunct 
to bandaging and report improved outcomes.
f. Elevation. Simple elevation (particularly by bed rest) of 
a lymphedematous limb often reduces swelling, particu-
larly in Stage I of lymphedema. If swelling is reduced by 
antigravimetric means, the effect should be maintained 
by wearing of a low-stretch, elastic stocking/sleeve 
during daytime.
g. Low level laser. Reports with small numbers of patients 
and small meta-analysis have demonstrated efficacy of 
low level laser use for patients with lymphedema. More 
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robust changes are noted with reduction of pain and 
mobility of tissue than just pure lymphedema volume 
reduction. More studies with larger numbers of patients 
in diverse settings are needed to confirm these findings.
h. Aquatic therapy/ water-based exercise programs have 
gained some success due to the natural compression of 
water when exercising and improvements to skin condi-
tion. Not all patients (particularly those with wounds or 
skin issues) are candidates for aquatic therapy.
i. For appropriate patients, adjuvant devices such as 
ultrasound or shockwaves may be useful to help break 
up fibrous tissue, although no large patient series have 
been published.
j. Wringing out. “Tuyautage” or wringing out performed 
with bandages or rubber tubes is probably injurious to 
lymph vessels and should seldom if ever be performed.
Drug therapy
a. Diuretics. Diuretic agents are of limited use during the 
initial treatment phase of CDT and should be reserved 
for patients with specific co-morbid conditions or 
complications. Long-term administration of diuretics, 
however, is discouraged for it is of marginal benefit in 
treatment of peripheral lymphedema and potentially 
may induce fluid and electrolyte imbalance. Diuretic 
drugs may be helpful to treat effusions in body cavities 
(e.g., ascites, hydrothorax) and with protein-losing 
enteropathy as well as in those patients in palliative care. 
Patients with peripheral lymphedema from malignant 
lymphatic blockage may also derive benefit from a short 
course of diuretic drug treatment.
b. Benzopyrones. Oral benzopyrones, which have been 
reported to hydrolyze tissue proteins and facilitate 
their absorption while stimulating lymphatic collec-
tors, are neither an alternative nor substitute for CDT. 
The exact role for benzopyrones (which include those 
termed rutosides and bioflavonoids) as an adjunct is 
still not definitively determined including appropriate 
formulations and dose regimens. Coumarin, one such 
benzopyrone, in higher doses has been linked to liver 
toxicity particularly in some patients with specific liver 
enzyme defects.
c. Antimicrobials. Antibiotics should be administered for 
bona fide superimposed acute lymph stasis-related 
inflammations (cellulitis/lymphangitis or erysipelas). 
Typically, these episodes are characterized by erythema, 
pain, high fever and, less commonly, even septic shock. 
Mild skin erythema without systemic signs and symp-
toms does not necessarily signify bacterial infection. If 
repeated limb “sepsis” recurs despite optimal CDT, the 
administration of a prophylactic penicillin or broad spec-
trum antibiotic is recommended (continuance depends 
on medical risk/benefit assessment). Fungal infection, 
a common complication of extremity lymphedema, can 
be treated with antimycotic drugs. In most instances, 
washing the skin using a mild disinfectant followed by 
antibiotic-antifungal cream is helpful. Short-term use of 
anti-histamines and steroids in selected patients with in-
flammation has also been utilized by some practitioners.
d. Filariasis. To eliminate microfilariae from the blood-
stream in patients with lymphatic filariasis, the drugs 
diethylcarbamazine, albendazole, or ivermectin are rec-
ommended. Killing of the adult nematodes by these drugs 
(macrofilaricidal effect) is variable and may be associated 
with an inflammatory-immune response by the host with 
aggravation of lymphatic blockage. Short and long-term 
efficacy of antibiotics (e.g., penicillin or doxycyclin) sepa-
rate from general skin hygiene in patients with lymphatic 
filariasis to prevent elephantine trophic changes remains 
to be determined to gain wider acceptance.
e. Mesotherapy. The injection of hyaluronidase or similar 
agents to loosen the extracellular matrix is of unclear 
benefit and may actually be harmful.
f. Immunological therapy. Efficacy of boosting immunity 
by intraarterial injection of autologous lymphocytes is 
unclear and needs independent, reproducible evidence.
Recent proposals for the use of anti-inflammatory 
pharmaceuticals have not yet demonstrated efficacy and 
may face drawbacks if administered long-term.
g. Diet. No special diet has proved to be of therapeutic 
value for most uncomplicated peripheral lymphede-
ma. In breast cancerrelated lymphedema and in obese 
patients, weight reduction has been shown to help. 
Restricted fluid intake is not of demonstrated benefit 
for peripheral lymphedema. In chylous reflux syndromes 
(e.g., intestinal lymphangiectasia), a diet as low as pos-
sible or even free of long-chain triglycerides (absorbed 
via intestinal lacteals) and high in short and medium 
chain triglycerides (e.g., MCT absorbed via the portal 
vein) is of benefit especially in children. Specific vitamin 
supplements may be needed in very low or no fat diets. 
Some clinics suggest diets (e.g., enriched with omega 
3’s) that may lower inflammation, but evidence is not 
currently robust.
h. In complicated patients with lymphatic system over-
growth (lymphangiodysplasia) associated with lymphede-
ma, specialized centers may utilize pharmacotherapeu-
tic options such as octreotide, OK-432, rapamycin, or 
other anti-proliferative agents (these treatments are 
particularly used in newborns and children).
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Psychosocial rehabilitation
The magnitude of the relationships between negative 
psychological and psychosocial factors and lymphedema has 
been documented as a cause of nonadherence to self-man-
agement as well as diminution in quality of life. Psychosocial 
support, quality of life assessment-improvement program, 
and a patient self-efficacy assessment are integral compo-
nents of any lymphedema treatment.
Operative Treatment
Operations designed to alleviate peripheral lymphedema 
by enhancing lymph return have gained increased accept-
ance worldwide but in advanced stages usually require long-
term combined physiotherapy and/or other compression 
after the procedure to maintain edema reduction and 
ensure vascular/shunt patency. These microsurgical pro-
cedures currently provide the closest chance for a cure of 
lymph flow disorders. In carefully selected patients following 
full evaluations, these procedures act as an adjunct to CDT 
or are undertaken when CDT has clearly been unsuccessful 
(or has removed the fluid component). Recent research has 
also focused on a preventive aspect in high risk patients (in 
limited reports). Imaging is indispensable to identify func-
tional vessels or nodes to manipulate.
As with physical methods above, proponents report that 
greater success is found in those patients with early (Stage I) 
lymphedema (with the notable exception to liposuction, 
which is usually performed in later stages).
Worldwide, surgical resection (in several forms) is the 
most widely used operative technique to reduce the bulk of 
lymphedema (especially in genitalia cases). Liposuction to re-
duce excess fat deposition is becoming more widespread with 
surgeons in multiple countries now performing the procedure.
In some specialized centers, operative treatment within 
specific guidelines may now be a preferred approach de-
pending on the treatment team training and availability of 
various treatments.
It is noted that there is no clear clinical differen-
tial for choosing which of these different techniques to 
use for treating individual patients and no head-to-head 
comparisons or randomized studies of the techniques. In 
addition, many centers also use combinations of operative 
procedures (along with added non-operative methods) in 
their approach to treating patients making determination 
of individual treatment effects more difficult to evaluate.
Microsurgical procedures
This operative approach is designed to augment the 
rate of return of lymph to the blood circulation. The 
surgeon should be well-schooled in both microsurgery and 
lymphology and utilize appropriate imaging tools to docu-
ment efficacy. In general, microsurgical procedures must be 
performed with special caution in children. Experience with 
these procedures suggests that improved and a longer last-
ing benefit is forthcoming if performed early in the course 
of lymphedema before damage to the lymphatic wall and 
impaired lymphatic contractility have occurred.
a. Derivative methods. Lymphaticvenous (or lymphovenous) 
anastomoses (LVA) are currently in use at multiple 
centers around the world. These procedures have 
undergone confirmation of long-term patency (in some 
cases more than 20 years) and some demonstration of 
improved lymphatic transport (by objective physiologic 
measurements of long-term efficacy). Multiple lymphat-
icvenous anastomoses in a single surgical site with both 
the superficial and deep lymphatics, allow the creation 
of a positive pressure gradient (lymphatic-venous) and 
evade the phenomenon of gravitational reflux without 
interrupting the distal peripheral superficial lymphatic 
pathways. Some centers also practice lymph nodal-ve-
nous shunts as a derivative method.
b. Reconstructive methods. These sophisticated tech-
niques involve the use of a lymphatic collector (LLA) 
or an interposition vein segment (LVLA) to restore 
lymphatic continuity in lymphedema conditions due to 
a locally interrupted lymphatic system. Autologous lymph 
vessel transplantation mimics the normal physiology 
and has shown long-term patencies of more than 
10 years. This procedure generally has been restricted 
to unilateral peripheral lymphedema of the leg due to 
the need for one healthy leg to harvest the graft but it 
has also been utilized for bilateral upper extremity 
lymphedema where two healthy legs are available for 
lymphatic harvesting.
Vascularized Lymph Node Transplantation
Transplantation of superficial lymph nodes from an un-
involved area together with the vascular supply (VLNT) to 
the site of lymphadenectomy for cancer has been proposed 
both as a preventive and therapeutic approach to limb 
lymphedema.
Long-term followup data on risk and efficacy is scant 
along with the influence of adjunctive physical methods. 
There have been several reports of lymphedema devel-
oping in the donor area. While imaging has demonstrated 
blood flow to the transplanted nodes, sparse data have 
been published on lymph flow through the transplanted 
nodes. Further research showing long-term efficacy and 
improvement in techniques to avoid donor site lymphedema 
are needed. Some surgeons combine this procedure with 
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liposuction and postoperative compression claiming favorable 
outcome, which makes it difficult to evaluate the surgical 
procedure per se.
Liposuction
Liposuction (or suction-assisted lipectomy) using 
a variety of methods has been shown to completely reduce 
non-pitting, primarily non-fibrotic, extremity lymphedema 
due to excess fat deposition (which has not responded to 
non-operative therapy) in both primary and secondary 
lymphedema (and more limited studies in lipedema). Even 
patients with signs of fibrosis can benefit from the procedure 
when using power-assisted liposuction, which facilitates 
breaking down fibrosis especially in leg lymphedema. Similar 
to conservative treatment, long-term management requires 
strict patient adherence with dedicated continuous wearing 
of low-stretch elastic compression garments, which may 
be challenging in warmer climates and pose financial con-
siderations. This operation and followup are very different 
from cosmetic liposuction and should be performed by an 
experienced team of surgeons, nurses and physiotherapists 
to obtain and sustain optimal outcomes.
Newer investigations have focused on combining micro-
surgery with lymph vessel sparing liposuction in an effort to 
alleviate the need for continual compression.
Surgical Resection
The simplest operation is “debulking,” that is, removal of 
excess skin and subcutaneous tissue of the lymphedematous 
limb. The major disadvantage is that superficial skin lym-
phatic collaterals are removed or further obliterated. It can 
also be associated with significant scarring, risk of infection, 
and difficult wound healing. After intensive CDT, redundant 
skin folds may require excision. Debulking has been re-
ported to be useful mainly in treatment of the most severe 
forms of fibrosclerotic lymphedema (elephantiasis) and in 
cases of advanced genital lymphedema. Caution should be 
exercised in removing enlarged lymph nodes or soft-tissue 
masses (e.g., lymphangiomas) in the affected extremity as 
lymphedema may worsen thereafter. Operations including 
the Charles and Thompson procedures are seldom used 
when other options are available.
Tissue Engineering/Lymphatic  
(Re)Vascularization
The implantation of tubes to transport lymph or engineered 
tubes/devices to promote new substitute lymphatic growth 
have not yet documented long-term value in large studies, 
and these techniques are continuing to undergo investigation.
Omental transposition, enteromesenteric bridge opera-
tions, and implantation of threads to promote perilymphatic 
spaces (substitute lymphatics) have not shown long-term 
value and should be avoided without further published 
evidence.
Specialized Considerations
Chylous and other reflux syndromes are special disor-
ders which may benefit from CT- or MR-guided sclerosis, 
interventional radiology techniques, or operative ligation of 
visceral dysplastic lymphatics, and/or lymphatic to venous 
diversion to close and decompress leaking lymphatic ves-
sels after delineation by multimodal imaging. Assessment in 
children and even pre-natal care is expanding.
There has been recent work with implantation of sili-
cone tubes as artificial lymphatics, and new developments in 
coatings and techniques may produce added improvements.
Extratruncal disease (i.e., lymphatic malformations 
outside of the main trunks which may or may not be associ-
ated with arterial/venous malformations) are often treated 
with a variety of these surgical procedures (as well as with 
pharmacotherapy) in highly specialized centers.
Rehabilitation and even habilitation is a particularly 
necessary component of care.
Treatment Assessment/Followup
In each patient undergoing therapy, an assessment 
of limb volumes should be made before, during and af-
ter treatment. This volume can be measured by water 
displacement, derived from circumferential measure-
ments using the truncated cone formula, or by perometry. 
The excess volume (affected limb — unaffected limb) 
should be measured since limb volumes vary with weight 
increase/decrease of the patient as well as whether meas-
urements are made in the morning or afternoon. Only 
measuring the affected extremity can lead to unreliable 
values. It is desirable, however, that treatment outcomes be 
reported in a standardized manner in order to compare 
and contrast the effectiveness of various treatment protocols.
Additional assessments by imaging modalities such as 
LAS and NIRF to document functional changes in lymphatic 
drainage, DEXA, US, or MR imaging to determine volume 
and tissue compositional changes, tonometry/indurometry, 
bioelectrical impedance BIS or BIA), and tissue dielectric 
constant (TDC) to examine tissue alterations and fluid 
changes add scientific rigor to analysis of the outcomes of 
different treatment approaches.
Health Related Quality of Life (HRQOL) and patient 
perceptions of self-efficacy assessed by a variety of vali-
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dated disease specific instruments and visual analog scales 
of patients with lymphedema should be used in conjunction 
with physiological measures to evaluate effects of treatment.
Timing and longevity of assessments is an area that is 
recognized as a need but there are no good guidelines or 
model systems in place. Pre-treatment and pre-operative 
assessment (in the Prospective Surveillance model- Section I) 
should continue after treatment and likely should be life-long 
to include HRQOL, self-efficacy, and self-regulation meas-
ures. Data on long-term results will be useful in comparing 
treatment options and success, as well as enable patients to 
have the opportunity to participate in best-practice decisions.
Molecular Therapy
Despite ongoing basic research and clinical trials, molec-
ular treatments (e.g., administration of VEGF-C or other 
lymphatic-targeting molecules by various methods) have 
not yet been significantly translated to the clinic. While 
the addition of lymphatic growth (or inhibitory) factors is 
attractive, the applicability of these treatments is uncertain 
at this time and should be examined carefully in the context 
of co-morbid conditions (e.g., presence of cancer, cancer 
treatments, drug regimens). It is also apparent when exam-
ining the growth of new lymphatics in the laboratory that for 
all but the smallest microlymphatics a milieu of growth (and 
other) factors may be needed for initiation and development 
of functional macrolymphatics (and even more for the de 
novo development of a lymph node).
Research agenda
While recognizing and encouraging individual investiga-
tors to pursue many different avenues of research, some 
general directions can be formulated. Diagnostic tech-
niques need to be continually explored and developed, 
treatment options need confirmation and improvements 
with a particular focus on personalization, and better delin-
eation of prognosis is necessary. Multinational collaborative 
studies and innovative clinical research designs in addition 
to randomized control trials need to be done and are 
encouraged with the aim of translating new discoveries 
and potentially improved approaches more rapidly into 
the clinical arena. Ongoing epidemiologic studies on the 
incidence and prevalence of lymphedema regionally and 
worldwide will benefit from the further development and 
establishment of standardized, secure, intercommunicating 
database-registries.
Assessment of lymphedema risk and steps for lymphede-
ma prevention in different groups of at risk patients need 
to be determined.
Studies might include research on minimizing or pre-
venting secondary lymphedema through altered operative/ 
/nodal sampling techniques (e.g., sentinel node biopsy or 
precise anatomical knowledge of derivative pathways), 
vector control (as demonstrated in China) and prophylactic 
drugs for filariasis, identification of patients with heritable 
genetic defects for lymphangiodysplasia (lymphedema), and 
use of massage or compression where lymphatic drainage is 
subclinically impaired as documented by imaging techniques 
(e.g., LAS and NIRF).
Research in molecular lymphology including lymphatic 
system genomics, proteomics, and “systemomics” should 
be greatly expanded. With the cellular and molecular basis 
of lymphedema-associated syndromes better defined, an 
array of specific biologicallybased treatments including mod-
ulators of lymphatic growth and function should become 
available. Improved imaging techniques and physiological 
tests need to be devised to allow more precise non-invasive 
methods to measure lymph flow dynamics and lymphangion 
activity. Advances in imaging including molecular imaging 
techniques as well as development of new and improved 
technologies (e.g., NIRF and photoacoustics) to visualize 
the superficial and deep lymphatic system and soft tissues 
need to continue. These may become point of care devices 
available to all or even encompass wearable sensors for 
both early detection and treatment assessment possibly 
sent digitally through a mobile phone or over the internet. 
Telelymphology consultations and followup linkage of special-
ized centers to remote areas should enhance future care 
delivery. As knowledge accrues, the current crude classifi-
cation of lymphedema should be revisited and modified to 
include more encompassing clinical phenotype-genotype 
correlations based on anatomic and functional alterations 
in the lymphatic or associated affected systems. Accord-
ingly, treatment, whether by designer drugs, gene or stem 
cell therapy, tissue engineering, physical methods or new 
operative approaches, should be directed at preventing, 
reversing or ameliorating the specific lymphatic defect and 
restoring function and quality of life.
Conclusion
Lymphedema may be uncomplicated or complex but 
should not be neglected.
Accurate early diagnosis and effective therapy is now 
available which should be able to shift the focus to a more 
proactive rather than reactive approach. Randomized trials 
need to take place. Lymphology itself is now recognized as 
an important and distinct discipline in which clinicians from 
diverse specialties can be carefully trained and collaborate 
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to unravel the intricacies of the lymphatic system, lymph 
circulation, and related disorders. The emerging era of 
molecular lymphology and precision medicine tailored to the 
individual patient is likely to result in earlier recognition of 
a potential problem, improved understanding, evaluation, 
and treatment in the lymphology clinic, and in the larger 
context of clinical medicine.
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